Market closed
Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Ticker
$ABEO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
136
Website
ABEO Metrics
BasicAdvanced
$318M
-
-$1.55
1.70
-
Price and volume
Market cap
$318M
Beta
1.7
52-week high
$7.32
52-week low
$3.93
Average daily volume
2.1M
Financial strength
Current ratio
6.08
Quick ratio
5.991
Long term debt to equity
37.017
Total debt to equity
52.345
Interest coverage (TTM)
-15.26%
Management effectiveness
Return on assets (TTM)
-46.41%
Return on equity (TTM)
-216.57%
Valuation
Price to book
6.8
Price to tangible book (TTM)
6.8
Price to free cash flow (TTM)
-4.606
Growth
Earnings per share change (TTM)
-38.74%
3-year earnings per share growth (CAGR)
-58.40%
ABEO News
AllArticlesVideos
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Benzinga·4 days ago
US FDA approves Abeona's skin disorder therapy
Reuters·6 days ago
U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Abeona Therapeutics Inc. stock?
Abeona Therapeutics Inc. (ABEO) has a market cap of $318M as of May 05, 2025.
What is the P/E ratio for Abeona Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Abeona Therapeutics Inc. (ABEO) stock is 0 as of May 05, 2025.
Does Abeona Therapeutics Inc. stock pay dividends?
No, Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders as of May 05, 2025.
When is the next Abeona Therapeutics Inc. dividend payment date?
Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Abeona Therapeutics Inc.?
Abeona Therapeutics Inc. (ABEO) has a beta rating of 1.7. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.